Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 03, 2005. The report specifically details changes in director interests regarding Ordinary shares, rather than providing a comprehensive financial performance update.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to a specific share transaction:
- Share Sale Price: GBP 14.6636 per share.
- Shares Sold: 1,718 Ordinary shares.
Material Changes
The filing reports a transaction involving Mr. R Bondy, a person discharging managerial responsibility, on November 1, 2005:
- Option Exercises: Exercise of nil-price options over 2,094 shares (granted Feb 2002) and 2,094 shares (granted Feb 2003) under the SmithKline Beecham Mid-Term Incentive Plan (MTIP).
- Share Sale: Subsequent sale of 1,718 Ordinary shares.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is strictly a notification of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares held by Mr. R Bondy post-transaction.
- Confirm the market price of GSK shares on November 1, 2005, to contextualize the sale price of GBP 14.6636.
- Review the full terms of the SmithKline Beecham Mid-Term Incentive Plan (MTIP) referenced in the option grants.